Nevro Target of Unusually Large Options Trading (NYSE:NVRO)

Share on StockTwits

Nevro Corp (NYSE:NVRO) was the recipient of some unusual options trading on Monday. Stock traders bought 549 put options on the stock. This represents an increase of approximately 863% compared to the average volume of 57 put options.

NYSE:NVRO opened at $109.54 on Wednesday. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of -66.79 and a beta of 0.30. Nevro has a twelve month low of $34.75 and a twelve month high of $114.76. The stock’s 50 day moving average price is $101.01 and its two-hundred day moving average price is $79.96. The company has a quick ratio of 4.54, a current ratio of 5.87 and a debt-to-equity ratio of 0.91.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.27. The firm had revenue of $100.16 million for the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.37) EPS. As a group, analysts anticipate that Nevro will post -3.74 earnings per share for the current year.

In other Nevro news, VP Doug Alleavitch sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $110.00, for a total value of $110,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew H. Galligan sold 18,522 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $103.70, for a total value of $1,920,731.40. The disclosure for this sale can be found here. Insiders sold a total of 33,322 shares of company stock worth $3,538,891 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Quest Capital Management Inc. ADV acquired a new position in shares of Nevro during the 3rd quarter worth approximately $26,000. Metropolitan Life Insurance Co NY increased its position in shares of Nevro by 4.0% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 9,651 shares of the medical equipment provider’s stock worth $830,000 after purchasing an additional 367 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Nevro by 11.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 9,949 shares of the medical equipment provider’s stock worth $645,000 after purchasing an additional 1,019 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Nevro by 2.4% during the 3rd quarter. California State Teachers Retirement System now owns 46,608 shares of the medical equipment provider’s stock worth $4,007,000 after acquiring an additional 1,095 shares during the last quarter. Finally, Quantamental Technologies LLC acquired a new position in shares of Nevro during the 2nd quarter worth approximately $75,000.

NVRO has been the topic of several research reports. JMP Securities boosted their target price on Nevro to $115.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Oppenheimer upgraded Nevro from a “market perform” rating to an “outperform” rating and set a $106.00 target price on the stock in a research note on Thursday, November 7th. Zacks Investment Research upgraded Nevro from a “sell” rating to a “hold” rating and set a $67.00 target price on the stock in a research note on Tuesday, August 13th. Leerink Swann set a $98.00 target price on Nevro and gave the company a “buy” rating in a research note on Friday, August 23rd. Finally, Canaccord Genuity boosted their target price on Nevro from $59.00 to $88.00 and gave the company a “hold” rating in a research note on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $86.10.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: Initial Coin Offerings entail a high degree of risk

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Netflix  Receives Media Impact Score of 0.36
Netflix Receives Media Impact Score of 0.36
New Energy Systems Group.  Receives News Impact Score of -5.00
New Energy Systems Group. Receives News Impact Score of -5.00
Boeing  Earning Extremely Critical Press Coverage, Analysis Shows
Boeing Earning Extremely Critical Press Coverage, Analysis Shows
Borr Drilling Limited’s  Lock-Up Period To Expire  on January 27th
Borr Drilling Limited’s Lock-Up Period To Expire on January 27th
Invesco CEF Income Composite ETF  Sets New 12-Month High After Dividend Announcement
Invesco CEF Income Composite ETF Sets New 12-Month High After Dividend Announcement
MSC Industrial Direct  Stock Price Down 7.4% on Insider Selling
MSC Industrial Direct Stock Price Down 7.4% on Insider Selling


© 2006-2020 Ticker Report